Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

  • 1,
  • 2, 3,
  • 1,
  • 1,
  • 4, 5, 6,
  • 3,
  • 3,
  • 1,
  • 3, 7,
  • 3, 8,
  • 3, 9,
  • 1, 3, 10 and
  • 1, 11, 12Email author
Journal of Hematology & Oncology20169:133

https://doi.org/10.1186/s13045-016-0364-0

  • Received: 17 November 2016
  • Accepted: 28 November 2016
  • Published:

The original article was published in Journal of Hematology & Oncology 2015 8:115

Erratum

The original article [1] contains an omission of information in the Financial support sub-section of the Declarations section.

The authors would like to acknowledge the Andrew McDonough B+ Foundation for financial support of co-author Dr Yi-Cheng Wang throughout this study, and regret this inadvertent omission from the original publication.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA
(2)
Department of Biostatistics, University of Southern California, Los Angeles, CA, USA
(3)
Children’s Oncology Group, Monrovia, CA, USA
(4)
Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA
(5)
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
(6)
Weill Medical College of Cornell University, New York, NY, USA
(7)
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA
(8)
Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USA
(9)
Division of Hematology-Oncology, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA
(10)
Department of Pediatrics, University of Washington, Seattle, WA, USA
(11)
Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
(12)
Department of Epidemiology, University of Washington, Seattle, WA, USA

Reference

  1. Laszlo GS, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Hematol Oncol. 2015;8:115. doi:10.1186/s13045-015-0215-4.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement